Cargando…
SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein
T-cell responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been described in recovered patients, and may be important for immunity following infection and vaccination as well as for the development of an adoptive immunotherapy for the treatment of immunocompromised individ...
Autores principales: | Keller, Michael D., Harris, Katherine M., Jensen-Wachspress, Mariah A., Kankate, Vaishnavi V., Lang, Haili, Lazarski, Christopher A., Durkee-Shock, Jessica, Lee, Ping-Hsien, Chaudhry, Kajal, Webber, Kathleen, Datar, Anushree, Terpilowski, Madeline, Reynolds, Emily K., Stevenson, Eva M., Val, Stephanie, Shancer, Zoe, Zhang, Nan, Ulrey, Robert, Ekanem, Uduak, Stanojevic, Maja, Geiger, Ashley, Liang, Hua, Hoq, Fahmida, Abraham, Allistair A., Hanley, Patrick J., Cruz, C. Russell, Ferrer, Kathleen, Dropulic, Lesia, Gangler, Krista, Burbelo, Peter D., Jones, R. Brad, Cohen, Jeffrey I., Bollard, Catherine M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746091/ https://www.ncbi.nlm.nih.gov/pubmed/33331927 http://dx.doi.org/10.1182/blood.2020008488 |
Ejemplares similares
-
Coronavirus-Specific T-Cells Can be Rapidly Expanded from Convalescent Donors for Potential Clinical Use
por: Keller, Michael D., et al.
Publicado: (2021) -
Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease
por: Kinoshita, Hannah, et al.
Publicado: (2022) -
Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency
por: Kinoshita, Hannah, et al.
Publicado: (2021) -
T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1
por: Harris, Katherine M., et al.
Publicado: (2020) -
Transcriptomic analysis reveals optimal cytokine combinations for SARS-CoV-2-specific T cell therapy products
por: Durkee-Shock, Jessica, et al.
Publicado: (2022)